Janssen Discontinues Collaboration and License Agreements with Bavarian Nordic in Hepatitis B and Human Papillomavirus
NEW BRUNSWICK, NJ, May 9, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN® (Modified Vaccinia Ankara - Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses. Janssen remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing.No clinical studies in hepatitis B have been initiated by Janssen utilizing the MVA-BN® technology.Janssen will continue to prioritize investigation of its hepatitis B combination therapies using alternative investigational vaccine platforms and therapeutics within its broad portfolio and has multiple studies ongoing. Hepatitis B remains a critical global health issue, affecting an estimated 296 million people worldwide, and claiming nearly 900,000 lives every year.[1] Through its diverse scientific approach, Janssen is determined in its pursuit of a functional cure* for chronic hepatitis B to improve health outcomes for those living with the disease.There has been widespread uptake of effective, preventive vaccines against human papillomaviruses.[2] Due to this and the prioritization of other programs, Janssen will not be focusing R&D efforts on a therapeutic vaccine against human papillomaviruses at this time. Janssen...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Allergy & Immunology | Brain | Cancer & Oncology | Cardiology | Cardiovascular | Centers for Disease Control and Prevention (CDC) | Cervical Cancer Vaccine | Covid Vaccine | COVID-19 | Ebola | Ebola Vaccine | Genital Warts | Health Management | Heart | Hepatitis | Hepatitis B | Hepatitis Vaccine | Human Papillomavirus (HPV) | Hypertension | Infectious Diseases | Influenza | Influenza Vaccine | International Medicine & Public Health | Learning | Legislation | Neurology | Neuroscience | Pharmaceuticals | Profits and Losses | Pulmonary Hypertension | Science | Study | Universities & Medical Training | Vaccines | WHO